The Tata Group-promoted Advinus Therapeutics is expecting a breakthrough for a diabetes molecule in about six months. The company is likely to license it to other companies, according to Tata Sons Executive Director R Gopalakrishnan.
Advinus has already completed the first-stage development of the molecule and is set to initiate talks with pharma companies for further drug trials, he added. At present, five full-discovery programmes are on for internal research.
Advinus has a collaboration with Merck (USA) for drug discovery in the area of metabolic diseases.
The company has a drug discovery centre in Pune that focuses on diabetes, obesity, lipid disorders, inflammatory diseases and neglected diseases like dengue and malaria. Its Bangalore centre has a collaboration with DNDi (Drugs for Neglected), he said.